Overview

Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant

Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare Reduced Intensity Conditioning protocols containing either Thymoglobuline or Alemtuzumab in patients undergoing allogeneic transplant from voluntary unrelated donors.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Gruppo Italiano Trapianto di Midollo Osseo
Treatments:
Alemtuzumab